Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106695 | 0.91 | TLR7 (0.36) | CYP2D6ACHECD274MAPTGABRA5 | |
| SCHEMBL13097376 | 0.88 | PARP14 (0.38) | ACHECNR1CNR2ADAM17 | |
| SCHEMBL13097324 | 0.83 | PARP14 (0.36) | CYP2D6ACHEBRD4CNR1CNR2 | |
| SCHEMBL13097117 | 0.82 | CYP2D6 (0.55) | CYP2D6CYP11B2CNR1CNR2MAPT | |
| SCHEMBL13097389 | 0.81 | FFAR1 (0.37) | CD274FFAR1MAPT | |
| SCHEMBL3098716 | 0.80 | PDE2A (0.39) | CYP2D6BRD4CNR1CNR2FFAR1 | |
| SCHEMBL13097264 | 0.80 | PDE2A (0.39) | CYP2D6BRD4CNR1CNR2 | |
| SCHEMBL13097011 | 0.79 | CYP2D6 (0.43) | CYP2D6CNR1CNR2FFAR1 | |
| SCHEMBL13096998 | 0.79 | CYP2D6 (0.42) | CYP2D6BRD4CNR1CNR2 | |
| SCHEMBL13106158 | 0.79 | TLR7 (0.38) | CYP2D6ACHEFFAR1ADAM17MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885ACHE 1567/4885PDE9A 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.